Patents Assigned to Purdue Pharmaceuticals, L.P.
  • Publication number: 20210198268
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Application
    Filed: March 15, 2021
    Publication date: July 1, 2021
    Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes Technologies
    Inventors: Robert CHAPMAN, Lonn S. RIDER, Qi HONG, Robert KUPPER, Donald J. KYLE
  • Publication number: 20210169810
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: July 17, 2020
    Publication date: June 10, 2021
    Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
  • Publication number: 20210094963
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Application
    Filed: June 12, 2020
    Publication date: April 1, 2021
    Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes Technologies
    Inventors: Robert CHAPMAN, Lonn S. RIDER, Qi HONG, Donald KYLE, Robert KUPPER
  • Publication number: 20210000747
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
  • Publication number: 20210000748
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
  • Publication number: 20210000749
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
  • Patent number: 10696684
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: June 30, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P, RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10689389
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: June 23, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Publication number: 20200087316
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 19, 2020
    Applicants: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Robert CHAPMAN, Lonn S. RIDER, Qi HONG, Donald KYLE, Robert KUPPER
  • Patent number: 10407434
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 10, 2019
    Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10259819
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: April 16, 2019
    Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Publication number: 20190070119
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: September 4, 2018
    Publication date: March 7, 2019
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10206881
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 19, 2019
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20190000767
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: August 28, 2018
    Publication date: January 3, 2019
    Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
  • Publication number: 20180369150
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: January 31, 2018
    Publication date: December 27, 2018
    Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
  • Patent number: 10130586
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: November 20, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10076498
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 18, 2018
    Assignees: Purdue Pharma L.P., Purdue Pharmaceuticals L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 10076499
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 18, 2018
    Assignees: Purdue Pharma L.P., Purdue Pharmaceuticals L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 10076497
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: September 18, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10071057
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: September 11, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder